
Australian blood products and vaccine giant CSL doesn't expect to be impacted by new US pharmaceutical tariffs, and neither does two smaller ASX-listed drug companies.
CSL said on Tuesday it was still working through details of US President Donald Trump's tariff proclamation, but its initial view was most of its US product sales wouldn't be subject to tariffs.